Table 4.

Characteristics of DANBLOCK, REDUCE-SWEDEHEART, and BETAMI

	DANBLOCK	REDUCE-SWEDEHEART	BETAMI
Inclusion criteria
Age	≥ 18 years	≥ 18 years	≥ 18 years
MI definition	The universal definition of MI	The universal definition of MI (type 1)	The universal definition of MI (type 1)
Randomized prior to	Day 14 after MI	Day 7 after MI	Not specified
Revascularization	No criteria for revascularization	Obstructive coronary artery disease documented by coronary angiography	PCI or thrombolysis during hospitalization
LVEF cutoff value	> 40%	≥ 50%	≥ 40%
Exclusion criteria	Any medical condition where beta-blocker therapy is indicated or contraindicated according to the treating physician	Any medical condition where beta-blocker therapy is indicated or contraindicated according to the treating physician	Any medical condition where beta-blocker therapy is indicated or contraindicated according to the treating physician
Primary endpoints	A composite of all-cause mortality and hospitalization for recurrent non-fatal MI, unstable angina pectoris, stroke, and acute decompensated heart failure	Time to the composite of death of any cause or MI	Time to the composite of all cause mortality or non-fatal MI
Expected number of randomized patients	3570	7000	10,000
Expected number of events	900	944	794
Expected number of events to contribute to a pooled meta-analysis	632	944	794
Individual study power if true HR was 1.2	0.619	0.797	0.732